Seven analysts have raised 2026 estimates for the company since May, boosted in part by its deal with Novo to sell its drugs
While typically mild and transient, injection site discomfort can impact treatment adherence and patient experience
Medication-specific factors significantly impact onset of action
Expected outcomes based on trial data: Average weight loss of 24.2% at 48 weeks (phase 2) Average weight loss of 28.7% at 68 weeks (phase 3, TRIUMPH-4) 100% of participants achieved 5% or greater weight loss 93% achieved 10% or greater 83% achieved 15% or greater Moderate weight loss protocol (8mg target) For researchers who want significant weight loss but have a lower tolerance for side effects, stopping the escalation at 8mg is a validated approach
also authorised as Zepbound for weight management, though NHS access for weight management depends on NICE guidance and local commissioning decisions [11] [12] Referral to a Tier 3 or Tier 4 specialist weight management service for more complex cases If you are interested in participating in a clinical trial involving retatrutide or similar investigational medicines, your GP may be able to refer you to a research centre
The good news is that her IBX employer-sponsored coverage will continue to cover her medications through July, when the current plan ends
